CVM:NYSEAMERICAN
CEL-SCI Corp
2,28 $
arrow_downward
-25,73%(-0,79) 1Д
1 мая, 16:00:00 GMT-4 · USD
search
Все символы
1Д
5ДН
1МЕС
6МЕС
С1ЯН
1ГОД
5ЛЕТ
МАКС
| Символ | Цена | Изменения | Динамика (%) |
|---|
insights_autoСоздание статистики для тикера CVM…
Открыть
2,84 $
Высокая
2,90 $
Низкая
2,25 $
Рын. кап.
19,28 млн
Объем
0,00
Макс. цена за 52 нед.
13,48 $
Мин. цена за 52 нед.
1,98 $
Прибыль на акцию
-5,24 $
Бета
0,70
Акции в обращении
8,46 млн
Число сотрудников
43
Новости
Из источников в интернете
Профиль
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
О компании "CEL-SCI Corp"
Генеральный директор-
Количество сотрудников43
Дата основаниямар. 1983
Штаб-квартираВьенна, Вирджиния, Соединенные Штаты Америки
Сектор-
Сайтcel-sci.com
Созданный ИИ контент может содержать ошибки. Подробнее…